Skip to main content

Clinical trial BiRD

A Retrospective and Prospective Observational Study of ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice Belgian ibrutinib Real-world Data (BiRD)

Organ LLC
Trial status Trial closed
Trial type
Prospective observational study
Academic trial Non
Sponsor Janssen-Cilag N.V.
BECT Identifier B322201628075
Inclusion criteria patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment
Last update